---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019851"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:58:43.343727+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eledon Pharma Q1 net loss $9.9M; ALS topline data expected June 2022

## Summary
- Net loss $9.9M ($0.69/diluted share) vs $8.5M ($0.57) in Q1 2021.
- Cash $76.7M as of March 31, 2022, down from $84.8M; runway into 2024.
- Phase 2a ALS trial fully enrolled; topline data anticipated in June 2022.
- First patient dosed in Phase 2a IgA Nephropathy trial; initial data late 2022.
- Non-human primate study of tegoprubart monotherapy in kidney allograft rejection completed.

## SEC filing metadata
- accession: 0001564590-22-019851
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000156459022019851/0001564590-22-019851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000156459022019851/eldn-8k_20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019851
- JSON: https://secwatch.observer/filing/0001564590-22-019851.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.